TORONTO, Oct. 16 /CNW/ - Spectral Diagnostics Inc. ("Spectral"), (TSX:
SDI), today announced the signing of an exclusive, five year distribution
agreement with Estor S.p.A. ("Estor") for commercial sales of its novel sepsis
test, the Endotoxin Activity Assay ("EAA(TM)"), in Italy. This agreement
builds upon the initial arrangement signed with Estor in June of this year.
Estor, a leading supplier of medical devices for the treatment of sepsis
technologies in Italy, will market and distribute Spectral's new assay
instrument and its reagents for use in emergency departments and intensive
care units.
"We are very pleased to solidify a long term relationship with Estor,"
stated Dr. Paul Walker, President & CEO of Spectral. "Early acceptance of our
EAA(TM) product in Italy has been positive and this new exclusive arrangement
should provide for consistent growth in the Italian marketplace over the term
of the agreement," added Dr. Walker.
"As the distributor of PMX, a device for the extracorporeal removal of
endotoxins in septic patients, we definitely need a proven diagnostic tool to
bundle with the therapy. Estor began its marketing campaign with the
successful launch of EAA(TM) during the last Italian meeting of the ICU
scientific society (SIAARTI) held in Perugia on October 11th and 12th", stated
Dr. Gualtiero Guadagni, Sales & Marketing Director of Estor.
Spectral is a developer of innovative technologies for rapid diagnostics.
Spectral provides accurate and timely information to clinicians enabling the
early initiation of appropriate and targeted therapy. Current products include
rapid diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range
of other biological reagents. Spectral's common shares are listed on The
Toronto Stock Exchange: SDI.
Information in this news release that is not current or historically
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, the future outlook
of Spectral and anticipated events or results are assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected.
%SEDAR: 00002006E
